1. Dong, Yi Na, Mercado-Ayón, Elizabeth, Coulman, Jennifer, Adeshina, Miniat W, Lynch, David R. 2024. The Regulation of the Disease-Causing Gene FXN. In Cells, 13, . doi:10.3390/cells13121040. https://pubmed.ncbi.nlm.nih.gov/38920668/
2. Lam, Christina, Gilliam, Kaitlyn M, Rodden, Layne N, Lynch, David R, Bidichandani, Sanjay. 2023. FXN gene methylation determines carrier status in Friedreich ataxia. In Journal of medical genetics, 60, 797-800. doi:10.1136/jmg-2022-108742. https://pubmed.ncbi.nlm.nih.gov/36635061/
3. Delatycki, Martin B, Bidichandani, Sanjay I. 2019. Friedreich ataxia- pathogenesis and implications for therapies. In Neurobiology of disease, 132, 104606. doi:10.1016/j.nbd.2019.104606. https://pubmed.ncbi.nlm.nih.gov/31494282/
4. Aguilera, Cinthia, Esteve-Garcia, Anna, Casasnovas, Carlos, Llecha, Núria, Padró-Miquel, Ariadna. 2023. Novel intragenic deletion within the FXN gene in a patient with typical phenotype of Friedreich ataxia: may be more prevalent than we think? In BMC medical genomics, 16, 312. doi:10.1186/s12920-023-01743-0. https://pubmed.ncbi.nlm.nih.gov/38041144/
5. Pilotto, Federica, Chellapandi, Deepika M, Puccio, Hélène. 2024. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia. In Trends in molecular medicine, 30, 117-125. doi:10.1016/j.molmed.2023.12.002. https://pubmed.ncbi.nlm.nih.gov/38272714/
6. Sivakumar, Anusha, Cherqui, Stephanie. 2022. Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich's Ataxia. In Frontiers in genome editing, 4, 903139. doi:10.3389/fgeed.2022.903139. https://pubmed.ncbi.nlm.nih.gov/35663795/
7. Chang, Joshua C, Ryan, Molly R, Stark, Marie C, Medicherla, Bala, Fonck, Carlos. 2024. AAV8 gene therapy reverses cardiac pathology and prevents early mortality in a mouse model of Friedreich's ataxia. In Molecular therapy. Methods & clinical development, 32, 101193. doi:10.1016/j.omtm.2024.101193. https://pubmed.ncbi.nlm.nih.gov/38352270/
智鼠故事 
